Clinical trial
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
NCT00280735 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00280735 |
|---|---|
| Title | Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC |
| Official title | Phase II Trial Exploring the Feasibility of Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA Non-Small Cell Lung Cancer |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, docetaxel |
| Enrollment | 75 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Jan 23, 2006 |
| Last update posted | Jul 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: